To see all protocols that comply with the WHO Essential Medicine List 
 Caution mucositis:

Mucositis is one of the major toxicities that limit the deliverability of pralatrexate. Close monitoring and early intervention may help to avoid dose alteration or interruption. Refer to 'Dose modifications' section for more information before prescribing. 

Patients with lymphoma should be considered for inclusion into clinical trials. Link to ALLG websiteANZCTR website and Lymphoma Australia website.

This protocol is based on limited evidence; please refer to the evidence section of this protocol for more information.

The information contained in this protocol is based on the highest level of available evidence and consensus of the eviQ reference committee regarding their views of currently accepted approaches to treatment. Any clinician (medical oncologist, haematologist, radiation oncologist, medical physicist, radiation therapist, pharmacist or nurse) seeking to apply or consult this protocol is expected to use independent clinical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/3455

16 Dec 2018